All In Biotech

Drug Trial Radar · NCT00873119

Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary

An Open-label Randomized Phase II Trial of Belinostat (PXD101) in Combination With Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Previously Untreated Carcinoma of Unknown Primary

Last checked: Nov 19, 2026Latest source record: Jul 28, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

89

Actual

Start

Feb 2009

Primary completion

Dec 2012

Study completion Dec 2012

Sponsor

Lead sponsor
Valerio TherapeuticsIndustry
Sponsor type
Industry
Collaborators
Spectrum Pharmaceuticals, Inc
First posted
Apr 1, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess efficacy and safety of belinostat in combination with carboplatin and paclitaxel in patients with previously untreated carcinoma of unknown primary.

Conditions

  • Carcinoma of Unknown Primary

Interventions

  • belinostat, carboplatin, paclitaxelDrug

  • carboplatin, paclitaxelDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free SurvivalTime frame: Tumor assessment every 6 weeks for the treatment period. Subsequent assessments every 6 weeks for the initial 6 months, then every 9 weeks for 6 months, then every 12 weeks for 12 months and then every 6 months until 5 years from the start of study

Locations

23 sites in 4 countries. Site status is shown where the registry gives one.

  • Florida Cancer Specialists

    Fort Myers, Florida

  • Northwest Georgia Oncology Centers

    Marietta, Georgia

  • Baton Rouge Medical Center

    Baton Rouge, Louisiana

  • Center for Cancers and Blood Disorders

    Bethesda, Maryland

  • Research Medical Center

    Kansas City, Missouri

  • Oncology Hematology Care Inc.

    Cincinnati, Ohio

  • South Carolina Oncology Associates

    Columbia, South Carolina

  • Chattanooga Oncology & Hematology Associates, PC

    Chattanooga, Tennessee

  • Tennessee Oncology Sarah Cannon Research

    Nashville, Tennessee

  • South Texas Oncology and Hematology

    San Antonio, Texas

  • Virginia Cancer Institute

    Richmond, Virginia

  • H:S Rigshospital, The Finsen Centre

    Copenhagen, Denmark

  • CRLCC Francois Baclesse, Oncologie medicale

    Caen, France

  • Centre Oscar Lambert

    Lille, France

  • Centre Léon Bérard, Oncologie

    Lyon, France

  • Centre Eugène Marquis

    Rennes, France

  • Centre Henri Becquerel, Oncologie Médicale

    Rouen, France

  • Institut de Cancerologie de la Loire

    Saint-Priest-en-Jarez, France

  • Institut Gustave Roussy IGR

    Villejuif, France

  • Carl-Gustav-Carus Medicinische Klinik und Poliklinik I

    Dresden, Germany

  • Kliniken Essen-Mitte

    Essen, Germany

  • ASKLEPIOS Klinik Altona

    Hamburg, Germany

  • Ostholstein-Onkologie

    Oldenburg in Holstein, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.